Media and Communications

News

2008 News Releases

Tuesday, December 23, 2008
Teva Announces Tentative Approval of Generic Seroquel® Tablets

Jerusalem, Israel, December 23, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca's antipsychotic agent Seroquel® (Quetiapine Fumarate) Tablets, Eq. 25 mg base, 50 mg base, 100 mg base, 150 mg base, 200 mg base, 300 mg base and 400 mg base. The brand product had annual sales of approximately $3.8 billion in the United States for the twelve months that ended September 30, 2008, based on IMS sales Read More »

Tuesday, December 23, 2008
Teva Completes Acquisition of Barr

-- Transaction Extends Teva's Leadership in the U.S. and Key Global Markets; Strengthens Balanced Business Model and Enhances Growth Potential --Jerusalem, Israel,, December 23, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed its acquisition of Barr Pharmaceuticals, Inc. (NYSE: BRL). The combined company will have a significant presence in over 60 countries and generated approximately $13.6 billion in revenues on a pro-forma basis for the twelve months ended September 30, 2008. "This is truly an exciting day for us," said Shlomo Yanai, Read More »

Friday, December 19, 2008
U.S. Federal Trade Commission Clears Teva's Acquisition of Barr

Jerusalem, Israel and Montvale, NJ, December 19, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that the U.S. Federal Trade Commission ("FTC") has accepted the proposed consent order in connection with the pending acquisition of Barr by Teva and granted early termination of the Hart Scott Rodino waiting period. Under the consent order that has been executed by the parties and accepted for public comment by the FTC, Teva and Barr are required to divest certain formulations of 16 overlapping on-market generic drugs, Read More »

Friday, December 19, 2008
Teva and Barr Receive European Commission Approval for Acquisition

Jerusalem, Israel and Montvale, NJ, December 19, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that they received approval from the European Commission to proceed with Teva's acquisition of Barr.In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product overlap, representing approximately $6 million in the companies' annual sales.The companies continue to expect that the transaction will close this mo Read More »

Tuesday, December 09, 2008
Teva Receives Positive Results on AOK Tender

Jerusalem, Israel, December 9, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that it has received notification from Allgemeinen Ortskrankenkassen (AOK), Germany's largest health insurance company, on the results of the most recent tender for finished dosage pharmaceutical products. Teva, together with a partner, was chosen as the supplier of 15 contracts which represent approximately 20% of the tender value. The ex-factory prices (i.e. list prices before discounts), based on IMS, of these tender products for the 12 months ended October 31, 2008 was approximately 203 Read More »

Monday, December 08, 2008
Teva Draws on $1.75 Billion Bridge Financing in Connection with Pending Barr Acquisition

Secures Sufficient Cash On-Hand to Complete TransactionJerusalem, Israel, December 8, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that it has completed the drawdown of its combined $1.75 billion bridge loan facilities with Bank Hapoalim B.M. and Bank Leumi USA. The proceeds of the loans will be used towards funding Teva's previously announced acquisition of Barr Pharmaceuticals, Inc. (NYSE: BRL). Teva intends to fund the remaining cash portion of the consideration by using its cash and marketable securities on hand."Teva has secured the necessary funds to com Read More »

Tuesday, November 25, 2008
Teva Announces Agreement on Generic Pulmicort Respules® Patent Challenge

Jerusalem, Israel, November 25, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva's U.S. generic version of AstraZeneca's Pulmicort (Budesonide) Respules® including all claims for patent infringement and damages. Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The agreement releases Teva for all past U.S. sales of its generic budesonide respules and provides that any product already shipped by Teva will Read More »

Thursday, November 20, 2008
Teva Provides Update on Generic Pulmicort Repulses® Launch

Jerusalem, Israel, November 20, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces that further to its press release dated November 19, 2008, the United States District Court for the District of New Jersey has granted AstraZeneca's request for a temporary order restraining further sales of Teva's generic version of AstraZeneca's Pulmicort (Budesonide) Respules® pending the Court's decision on AstraZeneca's motion for a preliminary injunction. As part of the same ruling, AstraZeneca and its partner Par Pharmaceuticals are to suspend distribution of AstraZeneca's own authorized Read More »

Wednesday, November 19, 2008
Teva Receives First U.S. Approval for Generic Pulmicort Respules®; Commences Commercial Launch

Jerusalem, Israel, November 19, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca's Pulmicort (Budesonide) Respules®, 0.25 mg/2 mL and 0.5 mg/2 mL indicated for twice daily treatment of Asthma. Shipment of these products has commenced.Total annual sales of these strengths of the brand product were approximately $996 million in the United States for the twelve months that ended September 30, 2008 based on I Read More »

Wednesday, November 19, 2008
Teva Announces Agreement on Allegra® Patent Challenge

Jerusalem, Israel, November 19, 2008 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an agreement with Aventis Pharmaceuticals, Inc., sanofi-aventis U.S. LLC and Albany Molecular Research, Inc. to settle patent litigation involving Teva's and Barr's U.S. generic versions of Aventis Pharmaceuticals' Allegra® (fexofenadine) 30mg, 60mg and 180mg tablets including all claims for patent infringement and damages. After entering into a separate agreement with Barr, Teva launched its gener Read More »

​​​